5-(3-溴苯基)-1H-吡唑-3-羧酸 | 1135821-47-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(3-溴苯基)-1H-吡唑-3-羧酸
• 中文别名: 5-(3-溴苯基)-1H-吡唑-3-甲酸
• 英文名称: 5-(3-bromo-benzyl)-2H-pyrazole-3-carboxylic acid
• 英文别名: 5-(3-Bromophenyl)-1H-pyrazole-3-carboxylic acid；3-(3-bromophenyl)-1H-pyrazole-5-carboxylic acid
• CAS: 1135821-47-4
• 化学式: C₁₀H₇BrN₂O₂
• 分子量: 267.082
• InChiKey: OWLGITCDNHDLLY-UHFFFAOYSA-N

物化性质

• 沸点：
  521.5±40.0 °C(Predicted)
• 密度：
  1.723±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  甲醇 、 5-(3-溴苯基)-1H-吡唑-3-羧酸 在 盐酸 、 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 为溶剂， 反应 16.0h， 以81%的产率得到methyl 3-(3-bromophenyl)-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF HISTONE DEACETYLASE
  [FR] INHIBITEURS DE L'HISTONE DÉACÉTYLASE

  摘要：

  这项发明涉及化合物和用于抑制HDAC酶活性的方法。更具体地，该发明提供了符合式(I)、(I)和N-氧化物、水合物、溶剂合物、药用可接受盐、前药和其复合物、外消旋和手性混合物、非对映异构体和对映体的化合物，其中L、M、n、R、W、X和Y如规范中定义的。

  公开号：

  WO2009055917A1
• 作为产物：
  描述：

  溴苯 在 aluminum (III) chloride 、 sodium methylate 、 一水合肼 、 溶剂黄146 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 5-(3-溴苯基)-1H-吡唑-3-羧酸
  参考文献：
  名称：

  5-Aryl-1H-pyrazole-3-carboxylic acids as selective inhibitors of human carbonic anhydrases IX and XII

  摘要：

  Inhibitory activity of a congeneric set of 23 phenyl-substituted 5-phenyl-pyrazole-3-carboxylic acids toward human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms I, II, IX and XII was evaluated by a stopped-flow CO2 hydrase assay. These compounds exerted a clear, selective inhibition of hCA IX and XII over hCAI and II, with Ki in two to one digit micromolar concentrations (4-50 mu M). Derivatives bearing bulkier substituents in para-position of the phenyl ring inhibited hCA XII at one-digit micromolar concentrations, while derivatives having alkyl substituents in both ortho-and meta-positions inhibited hCA IX with Kis ranging between 5 and 25 mu M. Results of docking experiments offered a rational explanation on the selectivity of these compounds toward CA IX and XII, as well as on the substitution patterns leading to best CA IX or CA XII inhibitors. By examining the active sites of these four isoforms with GRID generated molecular-interaction fields, striking differences between hCA XII and the other three isoforms were observed. The field of hydrophobic probe (DRY) appeared significantly different in CA XII active site, comparing to other three isoforms studied. To the best of our knowledge such an observation was not reported in literature so far. Considering the selectivity of these carboxylates towards membrane-associated over cytosolic CA isoforms, the title compounds could be useful for the development of isoform-specific non-sulfonamide CA inhibitors. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.052

文献信息

• INHIBITORS OF HISTONE DEACETYLASE
  申请人：METHYLGENE INC.

  公开号：US20140045850A1

  公开（公告）日：2014-02-13

  This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.

  本发明涉及化合物和方法，用于抑制HDAC酶活性。更具体地，本发明提供了公式（I），（I）和N-氧化物，水合物，溶剂化物，药学上可接受的盐，前药和其复合物，以及其外消旋和对映混合物，对映体和对映异构体的化合物，其中L，M，n，R，W，X和Y如规范中所定义。
• Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
  申请人：Burnham Institute for Medical Research

  公开号：EP2433496A1

  公开（公告）日：2012-03-28

  Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.

  本文公开的化合物是组织非特异性碱性磷酸酶抑制剂。所公开的化合物可用于治疗、预防或减轻血管钙化、动脉钙化和其他心血管疾病。
• TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION
  申请人：The Burnham Institute for Medical Research

  公开号：EP2164329A2

  公开（公告）日：2010-03-24
• US8119693B2
  申请人：——

  公开号：US8119693B2

  公开（公告）日：2012-02-21
• US8673911B2
  申请人：——

  公开号：US8673911B2

  公开（公告）日：2014-03-18